A new class of drugs called GLP-1 agonists, originally developed for type 2 diabetes, has shown promising results in reducing the risk of heart attacks and strokes in high-risk patients. These drugs work by mimicking the effects of a hormone called glucagon-like peptide-1, which helps regulate blood sugar levels and has additional benefits on the cardiovascular system. Recent clinical trials have demonstrated that GLP-1 agonists can significantly lower the risk of major adverse cardiovascular events, such as heart attacks and strokes, in patients with established cardiovascular disease or multiple risk factors. The drugs have also been found to promote weight loss and improve other metabolic parameters, making them a potential game-changer in the fight against obesity and related conditions. While more research is needed to fully understand the mechanisms and long-term effects, GLP-1 agonists represent a promising new approach to cardiovascular disease prevention and management.
Source: https://www.cnn.com/2024/09/18/health/glp-1-prevent-heart-attack-stroke/index.html